よむ、つかう、まなぶ。
資料4-3 レボホリナートカルシウム (21 ページ)
出典
| 公開元URL | https://www.mhlw.go.jp/stf/shingi2/0000198856_00024.html |
| 出典情報 | 医療上の必要性の高い未承認薬・適応外薬検討会議（第52回 8／31）《厚生労働省》 |
ページ画像
ダウンロードした画像を利用する際は「出典情報」を明記してください。
低解像度画像をダウンロード
プレーンテキスト
資料テキストはコンピュータによる自動処理で生成されており、完全に資料と一致しない場合があります。
テキストをコピーしてご利用いただく際は資料と付け合わせてご確認ください。
Onartuzumab in HER2-Negative, MET-Positive Gastroesophageal Adenocarcinoma: The
METGastric Randomized Clinical Trial. JAMA Oncol 2017; 3: 620-7.
12) Yoon HH, et al. Ramucirumab combined with FOLFOX as front-line therapy for advanced
esophageal, gastroesophageal junction, or gastric adenocarcinoma: a randomized, double-blind,
multicenter Phase II trial. Ann Oncol 2016; 27: 2196-203.
13) Bang YJ, et al. A phase II, randomised study of mFOLFOX6 with or without the Akt inhibitor
ipatasertib in patients with locally advanced or metastatic gastric or gastroesophageal junction
cancer. Eur J Cancer 2019; 108: 17-24.
14) Malka D, et al. FOLFOX alone or combined with rilotumumab or panitumumab as first-line
treatment for patients with advanced gastroesophageal adenocarcinoma (PRODIGE 17ACCORD 20-MEGA): a randomised, open-label, three-arm phase II trial. Eur J Cancer 2019;
115: 97-106.
15) Cleary JM, et al. FOLFOX plus ziv-aflibercept or placebo in first-line metastatic esophagogastric
adenocarcinoma: A double-blind, randomized, multicenter phase 2 trial. Cancer 2019; 125:
2213-21.
16) Mitani S, et al. A Phase II Study of Modified FOLFOX6 for Advanced Gastric Cancer Refractory
to Standard Therapies. Adv Ther 2020; 37: 2853-64.
17) 船坂知華子, 他 進行再発胃癌に対する Modified FOLFOX6 療法の有用性に関する検討.
癌と化学療法 2020; 47: 49-53.
18) Kondoh C, et al. Salvage chemotherapy with the combination of oxaliplatin, leucovorin, and 5fluorouracil in advanced gastric cancer refractory or intolerant to fluoropyrimidines, platinum,
taxanes, and irinotecan. Gastric Cancer 2018; 21: 1050-7.
19) Tsuji K, et al. Modified FOLFOX-6 therapy for heavily pretreated advanced gastric cancer
refractory to fluorouracil, irinotecan, cisplatin and taxanes: a retrospective study. Jpn J Clin
Oncol 2012; 42: 686-90.
20) Osumi H, et al. Modified FOLFOX6 as a first-line treatment for patients with advanced gastric
cancer with massive ascites or inadequate oral intake. Onco Targets Ther 2018; 11: 8301-7.
21) Masuishi T, et al. FOLFOX as first-line therapy for gastric cancer with severe peritoneal
metastasis. Anticancer Res 2017; 37: 7037-42.
22) Xu HB, et al. Capecitabine plus oxaliplatin (XELOX) compared with 5-fluorouracil/leucovorin
plus oxaliplatin (FOLFOXs) in advanced gastric cancer: meta-analysis of randomized controlled
trials. Eur J Clin Pharmacol 2015; 71: 589-601.
23) Caponigro F, et al. Gastric cancer. Treatment of advanced disease and new drugs. Front Biosci.
2005; 10: 3122-6.
24) Louvet C, et al. Phase II study of oxaliplatin, fluorouracil, and folinic acid in locally advanced or
metastatic gastric cancer patients. J Clin Oncol 2002; 20: 4543-8.
25) Al-Batran S-E, et al. Phase II trial of biweekly infusional fluorouracil, folinic acid, and oxaliplatin
21
METGastric Randomized Clinical Trial. JAMA Oncol 2017; 3: 620-7.
12) Yoon HH, et al. Ramucirumab combined with FOLFOX as front-line therapy for advanced
esophageal, gastroesophageal junction, or gastric adenocarcinoma: a randomized, double-blind,
multicenter Phase II trial. Ann Oncol 2016; 27: 2196-203.
13) Bang YJ, et al. A phase II, randomised study of mFOLFOX6 with or without the Akt inhibitor
ipatasertib in patients with locally advanced or metastatic gastric or gastroesophageal junction
cancer. Eur J Cancer 2019; 108: 17-24.
14) Malka D, et al. FOLFOX alone or combined with rilotumumab or panitumumab as first-line
treatment for patients with advanced gastroesophageal adenocarcinoma (PRODIGE 17ACCORD 20-MEGA): a randomised, open-label, three-arm phase II trial. Eur J Cancer 2019;
115: 97-106.
15) Cleary JM, et al. FOLFOX plus ziv-aflibercept or placebo in first-line metastatic esophagogastric
adenocarcinoma: A double-blind, randomized, multicenter phase 2 trial. Cancer 2019; 125:
2213-21.
16) Mitani S, et al. A Phase II Study of Modified FOLFOX6 for Advanced Gastric Cancer Refractory
to Standard Therapies. Adv Ther 2020; 37: 2853-64.
17) 船坂知華子, 他 進行再発胃癌に対する Modified FOLFOX6 療法の有用性に関する検討.
癌と化学療法 2020; 47: 49-53.
18) Kondoh C, et al. Salvage chemotherapy with the combination of oxaliplatin, leucovorin, and 5fluorouracil in advanced gastric cancer refractory or intolerant to fluoropyrimidines, platinum,
taxanes, and irinotecan. Gastric Cancer 2018; 21: 1050-7.
19) Tsuji K, et al. Modified FOLFOX-6 therapy for heavily pretreated advanced gastric cancer
refractory to fluorouracil, irinotecan, cisplatin and taxanes: a retrospective study. Jpn J Clin
Oncol 2012; 42: 686-90.
20) Osumi H, et al. Modified FOLFOX6 as a first-line treatment for patients with advanced gastric
cancer with massive ascites or inadequate oral intake. Onco Targets Ther 2018; 11: 8301-7.
21) Masuishi T, et al. FOLFOX as first-line therapy for gastric cancer with severe peritoneal
metastasis. Anticancer Res 2017; 37: 7037-42.
22) Xu HB, et al. Capecitabine plus oxaliplatin (XELOX) compared with 5-fluorouracil/leucovorin
plus oxaliplatin (FOLFOXs) in advanced gastric cancer: meta-analysis of randomized controlled
trials. Eur J Clin Pharmacol 2015; 71: 589-601.
23) Caponigro F, et al. Gastric cancer. Treatment of advanced disease and new drugs. Front Biosci.
2005; 10: 3122-6.
24) Louvet C, et al. Phase II study of oxaliplatin, fluorouracil, and folinic acid in locally advanced or
metastatic gastric cancer patients. J Clin Oncol 2002; 20: 4543-8.
25) Al-Batran S-E, et al. Phase II trial of biweekly infusional fluorouracil, folinic acid, and oxaliplatin
21